MORE►
all cash deal
Reata CEO Warren Huff [DI; Source photo: Reata]
Biogen To Acquire Plano-Based Biotech Reata Pharmaceuticals
by Lance Murray | Jul 28, 2023
Founded in 2002, rare disease drugmaker Reata has made significant advances in therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. The company's FDA-approved SKYCLARYS is the first and only approved treatment in the U.S. for Friedreich’s ataxia, a genetic nervous system disorder.
